<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS207185</article-id><article-id pub-id-type="doi">10.1101/2025.07.03.663006</article-id><article-id pub-id-type="archive">PPR1048020</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Phaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kemkem</surname><given-names>Yasmine</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Quinn</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kövér</surname><given-names>Bence</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Santambrogio</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kaufman-Cook</surname><given-names>James</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sherwin</surname><given-names>Olivia</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Scriba</surname><given-names>Laura D.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Brempou</surname><given-names>Dimitria</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Segoviano</surname><given-names>Miriam Vazquez</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cameron</surname><given-names>Dylan</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Berger</surname><given-names>Ilona</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Nonaka</surname><given-names>Daisuke</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Theodoropoulou</surname><given-names>Marily</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Pamporaki</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Carroll</surname><given-names>Paul V.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Izatt</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Chapple</surname><given-names>J Paul</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bornstein</surname><given-names>Stefan R.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bechmann</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Steenblock</surname><given-names>Charlotte</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Oakey</surname><given-names>Rebecca J.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Andoniadou</surname><given-names>Cynthia L.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="CR1">#</xref></contrib></contrib-group><aff id="A1"><label>1</label>Centre for Craniofacial and Regenerative Biology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King’s College London</institution></institution-wrap>, <city>London</city>, <postal-code>SE1 9RT</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A2"><label>2</label>Department of Medical and Molecular Genetics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King’s College London</institution></institution-wrap>, <city>London</city>, <postal-code>SE1 9RT</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A3"><label>3</label>Department of Internal Medicine III, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04za5zm41</institution-id><institution>University Hospital Carl Gustav Carus</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/042aqky30</institution-id><institution>Technische Universität Dresden</institution></institution-wrap>, <addr-line>Fetscherstrasse 74</addr-line>, <postal-code>01307</postal-code><city>Dresden</city>, <country country="DE">Germany</country></aff><aff id="A4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00j161312</institution-id><institution>Guy’s &amp; St. Thomas’ NHS Foundation Trust</institution></institution-wrap>, <city>London</city>, <postal-code>SE1 9RT</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A5"><label>5</label>School of Cancer &amp; Pharmaceutical Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King’s College London</institution></institution-wrap>, <city>London</city>, <postal-code>SE1 9RT</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A6"><label>6</label>Medizinische Klinik und Poliklinik IV, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jet3w32</institution-id><institution>LMU Klinikum</institution></institution-wrap>, LMU München, <city>Munich</city>, <postal-code>80336</postal-code>, <country country="DE">Germany</country></aff><aff id="A7"><label>7</label>Department of Clinical Genetics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00j161312</institution-id><institution>Guy’s &amp; St. Thomas’ NHS Foundation Trust</institution></institution-wrap>, <city>London</city>, <postal-code>SE1 9RT</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0574dzy90</institution-id><institution>William Harvey Research Institute</institution></institution-wrap>, Faculty of Medicine and Dentistry, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/026zzn846</institution-id><institution>Queen Mary University of London</institution></institution-wrap>, <city>London</city>, <postal-code>EC1M 6BQ</postal-code>, <country country="GB">United Kingdom</country></aff><author-notes><corresp id="CR1"><label>#</label>Corresponding author: Professor Cynthia L. Andoniadou, King’s College London, Floor 27 Tower Wing, Guy’s Campus, London, SE1 9RD, United Kingdom, <email>cynthia.andoniadou@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>14</day><month>07</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>07</day><month>07</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Phaeochromocytomas (PCCs) and paragangliomas (PGLs), are rare neuroendocrine tumours that arise in the neural crest (NC)-derived adrenal medulla and the paraganglia, respectively. Approximately 10%-15% of patients with PCCs and 35%-40% with PGLs go on to develop metastatic disease, leading to a reported median overall survival of 7 years. The development of prognostic markers and subsequent personal therapeutic strategies are hindered by a lack of understanding of tumourigenesis. In other organs, cells with stem-like properties are at the root of tumour initiation and maintenance, due to their ability to self-renew and give rise to differentiated cells. We have recently shown that, in the human adrenal, a subset of sustentacular cells, endowed with a support role, are in fact SOX2+ postnatal adrenomedullary stem cells, that are specified along the neural crest migratory route. In this study, we intended to determine if SOX2+ cells in PCCs and PGLs can behave as tumour-initiating stem cells. Using expression and transcriptomic studies, we demonstrate the presence of SOX2/<italic>SOX2</italic>-expressing cells across a broad range of PCCs and PGLs, irrespective of tumour aggressiveness, location, and causative mutation. <italic>In silico</italic> analyses reveal the co-expression of SOX2 and chromaffin cell markers in the tumour, and the active proliferation of these double-positive cells. Isolation of these cells <italic>in vitro</italic> in stem cell-promoting media, and their xenotransplantation on chicken chorioallantoic membranes, demonstrates that they have the potential to expand and metastasise <italic>in ovo</italic>, supporting their potential as tumour-initiating cells.</p></abstract><kwd-group><kwd>PPGL</kwd><kwd>PCC</kwd><kwd>PGL</kwd><kwd>Stem cells</kwd><kwd>SOX2</kwd><kwd>sustentacular cells</kwd><kwd>tumour-initiating cells</kwd><kwd>cancer stem cells</kwd><kwd>phaeochromocytoma</kwd><kwd>paraganglioma</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Phaeochromocytomas (PCC) and paragangliomas (PGL), collectively known as PPGL, are adrenal and extra-adrenal neuroendocrine tumours, respectively, composed of adrenaline- and noradrenaline-secreting chromaffin cells. They arise from neural crest-derived cells of the sympathetic and parasympathetic nervous system and according to WHO 2022 5th edition, all PPGLs have metastatic potential (<xref ref-type="bibr" rid="R1">1</xref>). With scarce therapeutic approaches available, the median survival rate of patients with metastatic PPGLs is ~7 years (<xref ref-type="bibr" rid="R2">2</xref>). Even PPGLs classified as benign are associated with high morbidity and mortality due to comorbidities related to excessive catecholamine production and secretion, that include hypertension, arrhythmia and stroke (<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R4">4</xref>).</p><p id="P3">PPGLs are associated with the highest degree of heritability in human neoplasms, with approximately 40% carrying germline mutations or deletions in at least one of several susceptibility genes that include <italic>VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2, RET, NF1, TMEM127, MAX, H3F3A</italic> and <italic>HIF2A</italic> (<xref ref-type="bibr" rid="R5">5</xref>). The most frequent cause of inherited PPGL are germline pathogenic variants in genes encoding for subunits of the mitochondrial succinate dehydrogenase (SDH) enzyme complex: <italic>SDHA, SDHB, SDHC</italic> and <italic>SDHD</italic> (<xref ref-type="bibr" rid="R6">6</xref>). Patients with <italic>SDHB</italic>-mutant PPGLs present with higher morbidity and mortality (<xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref>). Pathogenic germline <italic>SDHB</italic> variants have been detected in 42% of metastatic PPGLs (reaching 80% in paediatric metastatic PPGLs), but in a multivariate analysis on adult patients, they did not act as a prognostic factor of overall survival (<xref ref-type="bibr" rid="R2">2</xref>). In <italic>SDHB</italic>-mutant PPGLs secondary driver events in <italic>TERT</italic> or <italic>ATRX</italic> have been associated with metastatic disease (<xref ref-type="bibr" rid="R10">10</xref>). Combined germline and somatic driver genetic events are known in over 70% of cases, enabling the classification of PPGL into three clusters: cluster 1 (pseudohypoxia), cluster 2 (kinase signalling) and cluster 3 (WNT signalling) (<xref ref-type="bibr" rid="R11">11</xref>).</p><p id="P4">Despite our extensive knowledge of PPGL genetics, the exact cell-of-origin of PPGLs is currently unknown, and this together with their heterogeneity, severely limits the generation of <italic>in vivo</italic> experimental models and the road to targeted therapies. The possibility of a cancer stem cell (CSC) or tumour-initiating cell (TIC) has been proposed but not demonstrated for these tumours (reviewed in (<xref ref-type="bibr" rid="R12">12</xref>)). A previous study reported the expression of SOX2, a transcription factor associated with stem cells of multiple tissues, in 12% of PPGLs analysed by immunostaining on tumour microarrays (<xref ref-type="bibr" rid="R13">13</xref>). The study did not provide data to support stem cell function in these tumours. We recently identified a postnatal population of SOX2+ stem cells in the normal mouse adrenal medulla, which derives from the migratory neural crest population during embryonic development and which colonises the paraganglia and the adrenal medulla (<xref ref-type="bibr" rid="R14">14</xref>). That work demonstrated that SOX2+ adrenomedullary stem cells contribute to the generation of new chromaffin cells throughout life in mice, and are specified from neural crest-derived progenitor cells as a distinct population. Confirmation of their presence in normal human adrenals, coupled with the location of PPGLs along sites populated by the neural crest, raises the possibility that neural crest-derived SOX2+ cells might act as stem cells in PPGLs. In this study, we set out to determine if SOX2+ cells of PPGLs can behave as cancer stem cells and candidate cells-of-origin of these tumours.</p></sec><sec id="S2" sec-type="materials | methods"><title>Materials and Methods</title><sec id="S3"><title>Ethical Approval</title><p id="P5">All animal studies were performed under compliance with the Animals (Scientific Procedures) Act 1986, Home Office License P8D5E2773 (chicken), as well as KCL Biological Safety approval for project ‘Function and Regulation of Adrenal Stem Cells in Mammals’. Foetal adrenals were received from the Human Development Biological Resource (HDBR)/project ID 200587. PPGL tumour studies were conducted under King’s College London and were approved by the Cornwall and Plymouth Health Research Authority, study title: Investigation of genetic and epigenetic marks in cancer, IRAS project ID: 216133, REC reference: 17/SW/0018. Formalin-fixed, paraffin-embedded (FFPE) tumour and adrenal tissue samples with pathologically confirmed PPGLs were prepared by the Tumour and Normal Tissue Bank (TNTB) of the BioBank Dresden, originate from the archive of the Institute of Pathology (EK 59032007) of the University</p><p id="P6">Hospital Dresden. Patients were included from the Registry and Repository of biological samples of the European Network for the Study of Adrenal Tumours (ENS@T, EK 407122010), the Prospective Monoamine-producing Tumour study (PMT study; EK 189062010) and/or PROSPHEO (NCT03344016; EK 210052017), all of which had ethical approval at the University Hospital Carl Gustav Carus Dresden. Informed consent was obtained from all patients. Additional FFPE tumour samples were obtained from Queen Mary under study title: Genetics of Endocrine Tumours (Cambridgeshire Research Ethics Committee Reference MREC 06/Q0104/133. Normal adrenal human tissue samples were obtained from the University Hospital Würzburg (Germany). Normal adrenal glands were collected as part of tumour nephrectomy and proven to be histologically normal. Informed consent was obtained for all samples; patients were not compensated for participation.</p></sec><sec id="S4"><title>Chorioallantoic membrane (CAM) assays</title><p id="P7">Fertilised Shaver Brown eggs were purchased from Medeggs Ltd.Developmental. Day 0 corresponds to the day eggs were placed in an egg incubator set at 37.8°C/60% humidity. Four days later, eggs were windowed using curved spring scissors, exposing the CAM. Windows were sealed and eggs placed in the incubator until day 10, when isolated stem cells were seeded onto the CAM. 25μl of a single-cell suspension (100,000 cells) were pipetted onto the CAM, within a 6mm diameter silicone ring. Eggs were sealed and placed back in the incubator until collection on Day 14. Chicks were killed by Schedule 1 method. Resected CAM and dissected chick’s lungs were washed in PBS and fixed accordingly.</p></sec><sec id="S5"><title>Primary culture of adrenomedullary and PPGL-derived stem cells</title><p id="P8">PPGL tumours and adrenal glands were dissociated using an enzymatic digestion solution of 50μg/ml DNAse I (Sigma, CAT#D5025), 10mg/ml Collagenase II (Worthington, CAT#LS004177), 2.5μg/ml Fungizone (Gibco, CAT#15290026), 0.1X Trypsin-EDTA (Sigma, CAT#59418C) in 1X Hank’s Balanced Salt Solution (HBSS) (Gibco, CAT#14025050). Samples were sequentially incubated at 37°C and manually triturated, until reaching a single-cell suspension. Dissociation enzymes were deactivated with serum-rich base medium (DMEM/F-12 (Gibco, CAT#31330-038) + 5% FBS (Merk, CAT#F0804) + 50μl/ml Penicillin-Streptomycin (Gibco, CAT#15070063). The cell suspension was centrifuged, and the pellet was resuspended and plated in stem-cell promoting media: base media + 20ng/ml bFGF (R&amp;D Systems, CAT#234-FSE) + 50μg/ml cholera toxin (Sigma, CAT#C8052). For immunostaining, cells were plated on glass coverslips coated with 0.1% gelatine diluted in PBS. For CAM assays, stem cell colonies were expanded in stem-cell promoting media. On transplantation day, cells were trypsinised, labelled with a green-fluorescent chloromethyl derivative of fluorescein diacetate (CMFDA) intracellularly-activated CellTracker dye (ThermoFisher, CAT#C7025) as per the manufacturer’s instructions. Labelled cells were resuspended in stem-cell promoting media as a single-cell suspension for seeding onto CAM.</p></sec><sec id="S6"><title>Tissue processing for immunofluorescence and immunohistochemistry</title><p id="P9">For paraffin-embedding, resected grafts/CAMs were fixed in 10% neutral buffered formalin (NBF) (Sigma, CAT#HT501128) overnight at room temperature, on a roller. The following day, samples were washed and gradually dehydrated using ethanol series. Paraffin-embedded samples were sectioned at 5μm thickness. Chicks’ lungs were cryo-embedded. For this, they were fixed in 4% PFA at 4°C overnight. Samples were washed and placed in a cryoprotective 30% Sucrose/PBS solution overnight at 4°C. Samples were embedded in Optical Cutting Temperature compound (VWR, 361603E), flash-frozen, and cryo-sectioned at 15μm thickness.</p></sec><sec id="S7"><title>Immunofluorescence and immunohistochemistry</title><p id="P10">Paraffin sections were de-paraffinised with Neoclear and were gradually rehydrated in decreasing concentrations of ethanol. Antigen retrieval was performed in a decloaking chamber NXGEN (Menarini Diagnostics, CAT#DC2012-220V) at 110°C for 3 min using Dako Target Retrieval Solution, pH 9.0 (Agilent, CAT#S236784-2), as per the supplier’s instructions.</p><p id="P11">Immunohistochemistry was performed using the ImmPRESS Excel Amplified HRP Polymer Staining Kit Anti-Rabbit IgG (Vector Laboratories, CAT#MP-7602-50) as per the supplier’s instructions, using a rabbit anti-SOX2 antibody (Abcam, CAT#ab92494 ; 1:500). Nuclei were counterstained with Vector Haematoxylin QS (Vector Laboratories, CAT#H- 3404-100) and slides were mounted in VectaMount Permanent Mounting Medium (Vector Laboratories, CAT#H-5000-60).</p><p id="P12">Immunofluorescence staining was performed as follows: sections were blocked at room temperature for 1h in a 10% Donkey Serum Blocking Buffer (0.15% glycine, 2 mg/ml BSA, 0.1% Triton X-100 in PBS). Sections were then incubated overnight at 4°C with primary antibody diluted in 1% Donkey serum/Blocking Buffer (mouse anti-HNA (Merck, CAT#MAB4383, 1:300). Following three five-minute washes in PBS + 0.1% Triton X-100 (PBST), sections were incubated in secondary fluorophore-conjugated antibodies (Goat anti-mouse594 (Abcam, CAT#ab150116, 1:500) and DAPI (Abcam, CAT# ab228549, 1:5,000) in 1% Donkey Serum/Blocking Buffer.</p><p id="P13">Cryosections were air-dried and washed in PBS. Fixed cells were washed in PBS. In both cases, samples were blocked at room temperature for 1h in Blocking Buffer (1% BSA, 0.1% Triton X-100, 5% goat serum), followed by a 1-hour incubation in primary antibodies diluted in 1% Goat Serum/Blocking Buffer (mouse anti-Tyrosine Hydroxylase (BD Biosciences, CAT# 612300, 1:500 – goat anti-SOX2 (RD Systems, CAT# AF2018, 1:500)), and a 1-hour incubation in fluorophore-conjugated secondary antibodies (Biotinylated Goat anti-mouse (Abcam, CAT# Abcam ab6788, 1:500), Donkey anti-goat647 (Abcam, CAT# Abcam ab150131, 1:500). For tyrosine hydroxylase staining, a biotin-streptavidin amplification was performed. Following secondary biotinylated antibody incubation, sections were washed in PBST and incubated at room temperature for 1h with fluorescent-labelled streptavidin (Life Technologies, CAT#S32355, 1:500). DAPI (Abcam, CAT# ab228549, 1:5,000) was added in the last incubation. Samples were washed and mounted in Vectashield Antifade Mounting Medium (Vector Laboratories, CAT#H-1000-10).</p></sec><sec id="S8"><title>Imaging</title><p id="P14">Sections with immunohistochemistry staining were scanned using a Nanozoomer-XR Digital slide scanner (Hamamatsu). High magnification images were acquired with an Olympus BX34F Brightfield microscope. Cell culture images were obtained with an Olympus Phase Contrast microscope. Immunofluorescence imaging was performed using a Zeiss LSM980 confocal microscope (Zeiss Plan- Apochromat 20×/0.8 dry objective). Z-stacks were acquired with a 0.75μm step. Imaging files were processed with Fiji and Nanozoomer Digital Pathology view. Figures were created in Adobe Photoshop version 26.6.0.</p></sec><sec id="S9"><title>Computational studies</title><sec id="S10"><title>scRNA-seq and snRNA-seq dataset acquisition</title><p id="P15">PPGL tumour samples were obtained directly from the Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) operating theatres. Patients were enrolled to this study through the departments of endocrinology and clinical genetics in GSTFT. All patients enrolled provided written, informed consent which granted access to tumour tissues and clinical data. Following resection, tumour samples were immediately reviewed and dissected by an expert clinical pathologist. Confirmed PPGL tumour samples were then transferred to our laboratory where they were either snap frozen and stored at -80°C or they underwent dissociation in a single-cell suspension in expectation of immediate scRNA-sequencing. Single-cell dissociation was performed using an enzymatic digestion of 10μl/ml DNAse I (Sigma, CAT#D5025), 20μl/ml FBS (Thermo Fisher Scientific, CAT #10270106), 10mg/ml Collagenase II (Worthington, CAT#LS004177), 1mg/ml Dispase-II (Merck, CAT#SCM133) and 40U/ml RNaseOUT (Thermo Fisher Scientific, CAT#10777019) in 1ml of 1X Hank’s Balanced Salt Solution (HBSS) (Gibco, CAT#14025050). Samples were sequentially incubated at 37 °C and intermittently mechanically dissociated and vortexed throughout. Samples were then passed through a 40μm filter (Cole-Parmer, CAT# UY-06336-63) and centrifuged. The enzyme dissociation mix was removed, and the pellet was washed with and eventually resuspended in HBSS and 5% FBS (Thermo Fisher Scientific, CAT #10270106). The single-cell suspension was then inspected under the microscope using Trypan Blue Solution, 0.4% (Thermo Fisher Scientific, CAT#15250061) for cellular number and viability. Frozen samples underwent nuclei extraction as per 10X protocols. Samples were kept at 4°C throughout. 3-50mg of frozen PPGL tumour tissue was transferred to a pre-chilled Sample Dissociation Tube (10X, CAT#2000564) with 200μl of Lysis Buffer (Lysis Reagent (10X, CAT#200558), Reducing Agent B (10X, CAT#200087) and Surfactant A (10X, CAT#2000559). Samples were dissociated mechanically and 300μl of Lysis Buffer was added. The samples were incubated on ice for 8 minutes. Dissociated tissues were then centrifuged through a pre-chilled Nuclei Isolation Column (10X, CAT#2000562). Flowthrough was vortexed and centrifuged, and the pellet was resuspended with 500μl of Debris Removal Buffer (10X, CAT#200560). Samples were centrifuged and supernatant was removed before the pellet was resuspended in 1ml of Wash and Resuspension Buffer (1X PBS, 10% BSA and RNase Inhibitor (10X, CAT#2000565)). This was repeated until once depending on debris, with the final pellet resuspended in 50-500μl Wash and Resuspension Buffer. The suspension was then inspected for nuclei number, viability, debris and clumping using Trypan Blue Solution, 0.4%. Single cells/nuclei were processed on the Chromium iX instrument using 3’ v3.1 gene expression profiling reagents (10x Genomics) to generate GEMs (gel bead-in-emulsion) for cell barcoding. Cells were loaded on the chip with an aim to capture 8,000-10,000 cells per sample. Full length cDNA was generated from poly-adenylated mRNA and amplified. Dual indexed sequencing libraries were prepared from the amplified cDNA and final libraries were evaluated on the Agilent TapeStation 4200 using a High Sensitivity D5000 ScreenTape (Agilent Technologies). The libraries were then pooled and sequenced on NextSeq 2000 (Illumina) at a depth of approximately 20,000 read pairs per cell.</p></sec><sec id="S11"><title>Pre-processing for samples collected in this study</title><p id="P16">Samples were aligned to the GRCh38 reference genome using CellRanger 9.0.1 (10X Genomics) with default settings, meaning that intronic reads were also included for both single-cell and single-nucleus samples.</p></sec><sec id="S12"><title>Additional publicly available samples</title><p id="P17"><italic>SDHB</italic> PPGL single-nucleus RNA-seq samples were accessed from the corresponding Figshare of Flynn et al. (doi.org/<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/s41467-025-57595-y">10.1038/s41467-025-57595-y</ext-link>) <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.25792479">https://doi.org/10.6084/m9.figshare.25792479</ext-link>. The Figshare folder contained the CellRanger output matrices, from which the raw_feature_barcode matrix was used as input. Patient metadata for the corresponding samples was also accessed from the supplementary material of Flynn et al. (doi.org/<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/s41467-025-57595-y">10.1038/s41467-025-57595-y</ext-link>). Additional datasets for healthy adrenal medulla samples were accessed from the Figshare of Flynn et al. (doi.org/<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/s41467-025-57595-y">10.1038/s41467-025-57595-y</ext-link>) as well, though these are originally from Zethoven et al. (doi.org/<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/s41467-022-34011-3">10.1038/s41467-022-34011-3</ext-link>). Dataset identifiers for samples accessed from other publications were kept as original throughout.</p></sec><sec id="S13"><title>Quality control (QC) and further processing</title><p id="P18">To separate true cells from cell-free droplets, we first filtered out barcodes with less than 800 UMIs. Percentages of ribosomal, and mitochondrial counts were determined using the scanpy (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13059-017-1382-0">10.1186/s13059-017-1382-0</ext-link>) calculate_qc_metrics function with “RPS”, “RPL”, or “MT-” flags.</p><p id="P19">QC was then performed within scanpy using median +/- X * median absolute deviation filters, with x ranging from 4-5 for different metrics. Specifically, these included: percentage of mitochondrial counts (max = 25%, X=5), percentage of ribosomal counts (max = 30%, X=5), percentage of counts in top 20 genes (X=5), log1p total counts (X=4), log1p genes detected (X=4). Following this, doublets were identified and removed using the scrublet algorithm implemented in scanpy with default settings (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13059-017-1382-0">10.1186/s13059-017-1382-0</ext-link>).</p></sec><sec id="S14"><title>Dataset integration</title><p id="P20">To jointly analyse single-cells/-nuclei from all transcriptomic datasets, we used the scVI variational auto-encoder framework (doi.org/<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/s41592-018-0229-2">10.1038/s41592-018-0229-2</ext-link>). Specifically, we set each patient ID (one per dataset) as the batch_key and set the percentage of mitochondrial (pct_mito) and ribosomal (pct_ribo) counts as continuous covariates. The model was set up using 2 hidden layers and a latent space with 30 dimensions. The generative end of the model was specified to be negative binomial. The 30-dimensional latent space was then used for nearest-neighbor identification, Leiden clustering (resolution=0.4, flavor=“igraph”) and UMAP visualisations, all with scanpy implementations (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13059-017-1382-0">10.1186/s13059-017-1382-0</ext-link>).</p></sec><sec id="S15"><title>Cell type annotation</title><p id="P21">Leiden clusters of cells were annotated using established markers from previous work on PPGLs (doi.org/<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/s41467-025-57595-y">10.1038/s41467-025-57595-y</ext-link> ; doi.org/<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/s41467-022-34011-3">10.1038/s41467-022-34011-3</ext-link>) as follows: Chromaffin_cells: HAND2, SLC18A1, TH, PHOX2A ; Cortex_cells: CYP11B1, STAR ; Sustentacular_cells: SOX10, CDH19, S100B, SOX2 ; T_cells: CD4, TRBC1, TRBC2 ; Macrophages: CSF1R, CD163, C1QA ; Mast_cells: TPSAB1, TPSB2 ; B_cells: JCHAIN, CD79A, CD79B ; Endothelial_cells: ROBO4, FLT1 ; Fibroblasts: COL1A1, COL1A2, PDGFRB. Following initial overclustering, clusters with the same broad identities were merged.</p></sec><sec id="S16"><title>Pseudobulk differential expression analysis</title><p id="P22">To perform differential expression analysis, pseudobulk samples were generated from each cell type in each sample (where the cell type exceeded 30 cells) using the decoupleR package (doi.org/<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioadv/vbac016">10.1093/bioadv/vbac016</ext-link>). In the DE analysis, only cell types with at least 3 pseudobulk samples were kept. We then used the Limma-voom workflow (DOI: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/gb-2014-15-2-r29">10.1186/gb-2014-15-2-r29</ext-link>) to find cell type specific markers, with the model: “~ cell_type”, and contrasts between all cell-type pairs. Markers were assigned if they were significant in all comparisons. We applied a similar workflow to find differentitally expressed genes in metastasis and <italic>SOX2</italic> status, with the models “~ 0 + cell_type + cell_type:Metastasis” and “~ 0 + cell_type + cell_type:Chrom_SOX2_status”.</p></sec><sec id="S17"><title>Ligand-receptor interaction predictions</title><p id="P23">Ligand-receptor interaction prediction was performed using LIANA+ (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41556-024-01469-w">https://doi.org/10.1038/s41556-024-01469-w</ext-link>). This approach was chosen as it allows the use of an ensemble of ligand-receptor algorithms, as well as an integrated ligand-receptor interaction database. Here, 5 algorithms (CellPhoneDB with 1000 permutations, Connectome, log2FC, NATMI, SingleCellSignalR) were used as implemented in the aggregate_rank function using a merged version of databases (called “consensus” in LIANA+).</p></sec><sec id="S18"><title>LIANA+ signalling dotplots</title><p id="P24">Top ligand-receptor interactions were visualised using the native plotting functions within the LIANA+ package, using the commands li.pl.dotplot with the following arguments: colour=‘magnitude_rank’, size=‘specificity_rank’, inverse_size=True, inverse_colour=True, top_n=20, orderby_ascending=True. We have plotted interactions with Chromaffin cells as source, ranking by specificity. These were controlled through the “orderby”, “target_labels” and “source_labels” arguments.</p></sec><sec id="S19"><title>Heatmap plotting</title><p id="P25">Heatmaps were generated following pseudobulking of datasets with decoupleR and counts per million (CPM) and log1p normalising the resulting anndata objects. Heatmaps were then generated with the scanpy sc.pl.heatmap function with row-wise (e.g. per gene) min-max normalised values, with the arguments log=False, standard_scale=“var”.</p></sec><sec id="S20"><title>UMAP plotting</title><p id="P26">UMAPs were plotted using the scanpy function sc.pl.umap with the sort_order=True argument for featureplots to prevent the few expressing cells from being buried under the large number of non-expressing cells.</p></sec><sec id="S21"><title>Annotation of top TFs and signaling genes</title><p id="P27">A list of all human TFs was accessed from “<ext-link ext-link-type="uri" xlink:href="https://humantfs.ccbr.utoronto.ca/download/v_1.01/TF_names_v_1.01.txt">https://humantfs.ccbr.utoronto.ca/download/v_1.01/TF_names_v_1.01.txt</ext-link>“ and the LIANA “consensus” database was used to retrieve gene names relevant to cell-cell signaling (either ligands or receptors in the database).</p></sec><sec id="S22"><title>Code and data accessibility</title><p id="P28">Our code and processed data are available on <ext-link ext-link-type="uri" xlink:href="https://github.com/Andoniadou-Lab/SOX2_PPGL">https://github.com/Andoniadou-Lab/SOX2_PPGL</ext-link>. We provide a Jupyter Notebook of all Python code used for processing the datasets from CellRanger outputs. In addition, we provide an R script that was used for differential gene expression analysis with Limma-voom. Finally, we provide the cell type annotated AnnData object as a resource, allowing others to reproduce our work. Cell Ranger output files (raw and filtered count matrices) have been deposited on Figshare with the following DOI: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.6084/m9.figshare.29447750">10.6084/m9.figshare.29447750</ext-link>.</p></sec></sec></sec><sec id="S23" sec-type="results"><title>Results</title><sec id="S24"><title>SOX2+ cells are found in both phaeochromocytomas and paragangliomas, irrespective of mutation and tumour site</title><p id="P29">To determine the presence of putative stem cells in PPGL tumours, we focused on SOX2, which we previously established as a marker of progenitor/stem cells of the adrenomedullary lineage (<xref ref-type="bibr" rid="R14">14</xref>). Extending the previous report of stem cell markers in PPGLs (<xref ref-type="bibr" rid="R13">13</xref>), we tested for SOX2 expression on FFPE sections from a cohort of 19 PPGLs across different tumour sites, mutations and malignancy status. This cohort was composed of 12 adrenal PCCs and seven extra-adrenal PGLs, of which two were located in the carotid body, three abdominal, and two thoracic. Germline mutations in known genes were present in 15 patients, spanning <italic>NF1, SDHC, RET</italic> and <italic>SDHB</italic>, whilst three patients had somatic mutations in <italic>RET</italic> and <italic>VHL</italic>. Five of the tumours were metastatic, three of which harboured mutations in <italic>SDHB</italic>. Tumour data are found in <xref ref-type="table" rid="T1">Table 1</xref>. Immunostaining using antibodies against SOX2 identified positive cells in all tumours tested (<xref ref-type="fig" rid="F1">Figure 1 A-G</xref>). Heterogeneity was seen across different tumour locations. SOX2-positive cells ranged from 0.93% to 8.31% with an average of 4.54% SOX2+ of all nuclei. These data confirm that SOX2+ cells can be present across PPGLs irrespective of tumour type, metastatic status and mutation status.</p></sec><sec id="S25"><title>Single-cell analysis of PPGLs identifies a second <italic>SOX2</italic>-expressing population of chromaffin cells in tumours</title><p id="P30">To examine the molecular profile of tumour cell populations, we took advantage of published single-nuclei datasets (<xref ref-type="bibr" rid="R10">10</xref>) including nine PGLs (PGL20, PGL21, PGL23 to PGL29) and one PCC (PCC22). Additionally, we carried out single-cell analysis on three fresh tumour samples (PCC30, PGL31, PGL32) and single-nuclei analysis on an additional four frozen samples (PGL33 to PGL36). Of the seven new samples, two were metastatic (PGL32, PGL33) and three had germline mutations in <italic>SDHB</italic> and two in <italic>SDHD</italic> (one metastatic). All tumour data used for transcriptomic analysis are shown in <xref ref-type="table" rid="T2">Table 2</xref>. For comparisons, we included two published single-nuclei datasets of normal adrenal tissue (Healthy1 and Healthy2) (<xref ref-type="bibr" rid="R15">15</xref>).</p><p id="P31">Our analysis identified nine clusters of cells, including B-cells, Chromaffin cells, Cortex, Endothelial cells, Fibroblasts, Macrophages, Mast cells, Sustentacular cells and T-cells (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Sample distribution split between the two healthy samples and 17 tumours revealed the Cortex cell cluster derives almost entirely from the healthy adrenal controls, with representation from both groups in all other clusters. Key markers of cell populations known from mouse data are plotted in <xref ref-type="fig" rid="F2">Figure 2B</xref>; for chromaffin cells <italic>HAND2, SLC18A1, TH</italic> and <italic>PHOX2A</italic> and for the sustentacular population <italic>SOX10, CDH19, S100B</italic> and <italic>SOX2</italic>. The markers defining each cell population are listed in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>. Top sustentacular markers included previously undescribed <italic>PTPRZ1, KIRREL3, NKAIN3</italic> and <italic>CHST9</italic> (<xref ref-type="fig" rid="F2">Figure 2C</xref>). Proportions of all clusters in each of the datasets reveal variation in the sustentacular cells, with an over-representation of this cluster in PGL33 (31%) (<xref ref-type="fig" rid="F2">Figure 2D</xref>). Comparison of the Chromaffin cell cluster of tumours from patients with metastatic disease (7 tumours) to those from tumours that had not metastasised at the time of analysis (10 tumours), identified factors potentially associated with metastasis. The top candidate metastasis genes were <italic>GLCE, NELL1</italic>, both involved in the tumour matrisome (<xref ref-type="bibr" rid="R16">16</xref>), <italic>C17orf97</italic> (LIAT1), <italic>GHR</italic> encoding the growth hormone receptor, known to play a role in cancer metastasis and chemoresistance (<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref>), <italic>MND1</italic>, involved in cell cycle regulation and DNA repair and a prognostic marker for several cancers (<xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R21">21</xref>), and <italic>CREB5</italic>, proposed to promote invasion and metastasis in colorectal cancer and glioma (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>). <italic>EZH2</italic>, a histone methyltransferase that promotes cancer progression (<xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R25">25</xref>), as well as <italic>PIMREG</italic>, promoting aggressiveness through NF-kB and prognostic for several tumour types (<xref ref-type="bibr" rid="R26">26</xref>–<xref ref-type="bibr" rid="R28">28</xref>) are also in this group (<xref ref-type="fig" rid="F2">Figure 2E</xref>). <italic>EZH2, MND1</italic> and <italic>PIMREG</italic> have been independently identified as associated with metastasis in <italic>SDHx</italic> tumours using bulk RNA-seq (<xref ref-type="bibr" rid="R15">15</xref>).</p><p id="P32">Gene expression analysis of only the tumour samples confirms highest <italic>SOX2</italic> expression in the sustentacular cluster (<xref ref-type="fig" rid="F2">Figure 2F</xref>). Unexpectedly, there was also widespread <italic>SOX2</italic> expression across the Chromaffin cell cluster. Projection of <italic>SOX2</italic> expression (blue) combined with <italic>MKI67</italic> (yellow) marking cycling cells, demonstrated that double-positive cells (red) are located in the Chromaffin cell cluster (<xref ref-type="fig" rid="F2">Figure 2G</xref>, left). This confirms a population of cycling tumour cells that express <italic>SOX2</italic> but have chromaffin characteristics, unlike any population in healthy controls (<xref ref-type="fig" rid="F2">Figure 2G</xref>, right). Healthy controls and 15 out of 17 tumours contained <italic>SOX2</italic>+ cells (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>). The proportion of <italic>SOX2</italic>-expressing cells varied across tumours, with a group of five tumours having a substantially higher proportion of <italic>SOX2</italic>+ cells than healthy controls (<xref ref-type="fig" rid="F2">Figures 2H</xref>). Given the highly variable number of <italic>SOX2</italic>-expressing cells across samples, we decided to compare Chromaffin cells with higher proportion of <italic>SOX2</italic>+ cells to those with lower proportions or absence of <italic>SOX2</italic> (cut-off of 1%). Reassuringly, this analysis found the most differentially expressed transcription factor-encoding gene to be <italic>SOX2</italic>. Other highly ranked genes include <italic>HOXA7</italic>, whose protein product can function as an oncogene and contribute to malignancy (<xref ref-type="bibr" rid="R29">29</xref>–<xref ref-type="bibr" rid="R31">31</xref>), the proto-oncogene <italic>BRF2</italic> (<xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R33">33</xref>) (<xref ref-type="fig" rid="F2">Figures 2I</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref> for full list of significant factors). Our previous findings in mice demonstrated that SOX2+ cells have a major role in regulating cell proliferation of neighbouring cells through secretion of WNT6 (<xref ref-type="bibr" rid="R14">14</xref>). Comparative analysis of Chromaffin cells from tumours with a high SOX2 proportion versus those with lower/absent <italic>SOX2</italic>+ cell proportions, revealed differential expression of genes related to cell signalling. These include <italic>LGALS3BP</italic>, encoding a secreted factor involved in cancer progression (<xref ref-type="bibr" rid="R34">34</xref>), as well as the WNT protein-encoding genes <italic>WNT3, WNT10A, WNT11</italic> and <italic>WNT6</italic> (<xref ref-type="bibr" rid="R35">35</xref>–<xref ref-type="bibr" rid="R37">37</xref>) (<xref ref-type="fig" rid="F2">Figures 2J</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 2</xref>). To further investigate the relationships of chromaffin cells with the other tumourigenic populations, we carried out ligand-receptor analysis framework (LIANA+) analysis (<xref ref-type="bibr" rid="R38">38</xref>). This determines the intercellular communication inference between chromaffin cells and the other populations. Interestingly, the strongest, in magnitude, predicted signalling from chromaffin cells is to sustentacular cells, primarily through adhesion molecules ASHG, CNTN1, NCAM1, L1CAM, ALCAM, as well as through NRG3, PTN and APOO. Signalling to endothelial cells and fibroblasts is predicted through DLK1 and to macrophages by NRG1 (<xref ref-type="fig" rid="F2">Figure 2K</xref>). Taken together, these <italic>in silico</italic> data identify a malignant signature for PPGLs and support that tumour chromaffin cells aberrantly expressing SOX2, have distinct oncogenic gene expression and a secretory signature consistent with cancer promotion.</p></sec><sec id="S26"><title>PPGLs harbour cells that can be isolated in stem cell-promoting media and express SOX2 <italic>in vitro</italic></title><p id="P33">We previously established a protocol for the isolation of stem cells from the mouse adrenal medulla (<xref ref-type="bibr" rid="R14">14</xref>). We sought to determine if these culture conditions can be used to isolate stem cells from human tissues. Foetal adrenal medullae at 12, 17 and 19 post-conception weeks (PCW) were immunostained using antibodies against SOX2. Positive cells were identified in all conditions (<xref ref-type="fig" rid="F3">Figure 3A</xref>). Cells from an adrenal medulla at 19 PCW were dissociated into a single-cell suspension and plated in defined stem cell-promoting media (<xref ref-type="bibr" rid="R14">14</xref>). Cells adhered after 24 hours and colonies were visible at 96 hours (distinct by 72h), which could be expanded and passaged (<xref ref-type="fig" rid="F3">Figure 3B</xref>). This stem cell isolation protocol was also applied to two fresh PPGL samples, a benign PCC with no known mutations (PCC30) and a metastatic PGL with a mutation in <italic>SDHD</italic> (PGL33); transcriptomic analyses confirmed <italic>SOX2</italic>-expressing cells in both tumours (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>). Colonies were obtained from both tumours <italic>in vitro</italic> (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Immunofluorescence staining of PCC30 cultures, confirmed the expression of SOX2 in expanded colonies (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Immunofluorescence against TH did not detect chromaffin cells in the control foetal sample (not shown) but did in PCC30 (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Isolated cells were capable of at least three passages and recovered one freeze-thaw cycle. These findings confirm the presence of a PPGL cell population with <italic>in vitro</italic> clonogenic properties, consistent with stem cell potential.</p></sec><sec id="S27"><title>SOX2+ PPGL cells have tumour-initiating capacity <italic>in ovo</italic></title><p id="P34">We next sought to determine if <italic>in vitro</italic>-isolated SOX2+ PPGL cells can regenerate and metastasise in a xenograft assay. Isolated and expanded human SOX2+ PPGL cells PCC30, PGL33, as well as control foetal adrenal cultures were dissociated into a single-cell suspension and labelled with CellTracker CMFDA label, which converts into a green, fluorescent dye intracellularly, allowing cell tracing without dye transfer (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Purified and labelled <italic>in vitr</italic>o-isolated stem cells, were seeded onto fertilised chick chorioallantoic membranes (CAMs) as a single-cell suspension (100,000 cells per CAM) and incubated for four days (see <xref ref-type="fig" rid="F4">Figure 4B</xref> for schematic). CAM assays are established <italic>in vivo</italic> models for the study of tumour propagation, angiogenesis and metastasis (<xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R44">44</xref>). For each culture, grafting was carried out in a total of 10 eggs, over two independent experiments. Two eggs for PCC30, four eggs for PGL33 and four eggs for foetal controls survived and were analysed further. For PGL33, this led to the formation of tissue masses, presenting with green CMFDA label fluorescence (n=4) (<xref ref-type="fig" rid="F4">Figure 4C</xref>). This was not observed in CAMs seeded with PCC30 (n=2 surviving eggs), or control foetal adrenal-derived stem cells (n=4 surviving eggs). Immunofluorescence using an antibody against human nuclear antigen (HNA) and immunohistochemistry using antibodies against SOX2 confirmed cells within the <italic>de novo</italic> formed masses are derived from seeded human PGL33 stem cells and continue to express SOX2 protein (<xref ref-type="fig" rid="F4">Figure 4D</xref>). The lungs of each chicken embryo were harvested, fixed and processed for cryosectioning to enable analysis of possible metastasis through visualisation of green fluorescence. Detection of green CMFDA fluorescence in host chickens’ lungs revealed the presence of xenotransplanted, <italic>SDHD</italic>-mutant, PGL33-derived stem cells or their derivatives, confirming their potential to invade and metastasise (<xref ref-type="fig" rid="F4">Figure 4E</xref>). Immunofluorescence staining using antibodies against SOX2 and TH on chicken lungs from PGL33 xenotransplantations demonstrated the presence of SOX2+ cells, TH+ chromaffin cells, and infrequent double-positive cells (<xref ref-type="fig" rid="F4">Figure 4F</xref>). In summary, <italic>in vitro</italic>-isolated PPGL stem cells have tumour-initiating and metastatic capacity in a xenograft assay.</p></sec></sec><sec id="S28" sec-type="discussion"><title>Discussion</title><p id="P35">Identifying the cell of origin in tumours and cancers is critical for developing accurate experimental models of tumourigenesis, discovering prognostic markers, and the design of targeted therapies. The paradigm of cancer stem cells or tumour-initiating cells contributing directly to tumour formation and maintenance has been established in various solid tumours (<xref ref-type="bibr" rid="R45">45</xref>–<xref ref-type="bibr" rid="R51">51</xref>) We recently identified a neural crest-derived postnatal stem cell population expressing <italic>SOX2</italic>. Here, we demonstrate that <italic>SOX2+</italic> cells are consistently present in PPGLs, regardless of tumour location, malignancy status, or underlying genetic alterations. <italic>In silico</italic> analysis of 17 PPGL single-cell RNA sequencing datasets corroborates widespread <italic>SOX2</italic> expression in all but two tumours and defines a robust molecular signature linked to metastatic potential. In addition to <italic>EZH2, MND1</italic> and <italic>PIMREG</italic>, which are known promoters of cancer progression and have previously emerged as candidate metastatic markers in PPGL (<xref ref-type="bibr" rid="R15">15</xref>), we report additional novel candidates associated with metastatic behaviour. One particularly promising candidate is cyclic adenosine monophosphate (cAMP)-response element-binding protein 5 (<italic>CREB5</italic>). In colorectal cancer, <italic>CREB5</italic> can promote invasion and metastasis through activation of the receptor tyrosine kinase <italic>MET</italic>, and is associated with an unfavourable prognosis in multiple cancers including hepatocellular carcinoma, glioma, breast, prostate, and epithelial ovarian (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref>). These candidates require functional validation to determine the true drivers of metastasis, which will subsequently guide the identification of actionable therapeutic targets. Future work encompassing larger tumour cohorts will better resolve these drivers and aid in prognostic predictions.</p><p id="P36">Stem cells have been implicated in cancer relapse and metastasis (<xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R53">53</xref>) and can regenerate tumours when grafted (<xref ref-type="bibr" rid="R54">54</xref>). This study provides compelling evidence that PPGL-derived <italic>SOX2</italic>+ cells possess tumour-initiating capacity, with the ability to self-renew <italic>in vitro</italic>, regenerate and metastasise in xenotransplantation assays - key hallmarks of cancer stem cells (<xref ref-type="bibr" rid="R46">46</xref>). We identified two distinct <italic>SOX2</italic>+ populations within PPGLs; a sustentacular population, also present in healthy controls, and a tumour-specific subpopulation of chromaffin cells, echoing earlier histological observations (<xref ref-type="bibr" rid="R13">13</xref>). The presence of double-positive cells (expressing both <italic>SOX2</italic> and chromaffin markers) exclusively in tumours is particularly intriguing; these cells may be a unique stem cell of the tumours, since these are absent in normal adrenal tissue. Such cells may arise either from re-activation of a stem-like transcriptional programme in chromaffin cells, or from aberrant differentiation of sustentacular cells whilst they retain <italic>SOX2</italic> expression instead of downregulating this gene as in normal differentiation. Currently, it remains unclear whether metastasis in xenografts originates from <italic>SOX2</italic>+ tumour chromaffin cells or the <italic>SOX2</italic>+ sustentacular stem cell population.</p><p id="P37">Supporting a direct role in tumour growth, <italic>SOX2</italic>+ tumour chromaffin cells actively proliferate, unlike the more quiescent <italic>SOX2</italic>+ sustentacular cells. Moreover, they display a distinct transcriptomic signature that is enriched in genes promoting tumourigenesis and cancer progression. Our prior work demonstrated that WNT6 secretion by adrenomedullary stem cells regulates chromaffin cell proliferation (<xref ref-type="bibr" rid="R14">14</xref>). In the present study, the expression of several <italic>WNT</italic> genes, including <italic>WNT6</italic> and additional pro-tumourigenic factors by <italic>SOX2</italic>+ tumour chromaffin cells suggests a possible paracrine contribution to tumourigenesis, mirroring mechanisms observed in other cancers (<xref ref-type="bibr" rid="R55">55</xref>–<xref ref-type="bibr" rid="R61">61</xref>).</p><p id="P38">Overall, our findings establish that PPGLs contain cells with stem-like properties that can be isolated, expanded, and transplanted, and have the capacity to propagate tumours. These results provide the first functional evidence suggesting that <italic>SOX2</italic>+ cells in PPGLs possess the potential to serve as tumour cells of origin.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Figure 1</label><media xlink:href="EMS207185-supplement-Supplementary_Figure_1.pdf" mimetype="application" mime-subtype="pdf" id="d41aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S29"><title>Acknowledgements</title><p>We thank the King’s College London Biological Services facilities, the Genomics Research Platform, R&amp;D Department, Guy’s and St. Thomas’ NHS Trust. This research was supported by samples of the BioBank Dresden as a core facility of the Medical Faculty Dresden/Technical University Dresden and National Center of Tumor Diseases Dresden resource.</p><sec id="S30"><title>Funding</title><p>This work was funded by the Medical Research Council (grant APP40962) to CLA, the Paradifference Foundation to CLA and RO, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project no. 314061271, TRR 205: “The Adrenal: Central Relay in Health and Disease” to CLA, SRB, CS, NB and MT, and Project no. 288034826, IRTG 2251: “Immunological and Cellular Strategies in Metabolic Disease” to CLA, SRB and CS, The Bernice Bibby Research Trust to RJO and LI, The NIHR Biomedical Research Centre at Guy’s and St. Thomas’ NHSFT to MQ and GSK and the NIHR Biomedical Research Centre at Guy’s and St. Thomas’ NHSFT through the DRIVE-Health CDT to DB. BK and MVS were funded by the Wellcome Trust as part of the “Advanced Therapies for Regenerative Medicine Wellcome Trust PhD Programme (218461/Z/19/Z).</p></sec></ack><fn-group><fn fn-type="conflict" id="FN1"><p id="P39"><bold>Declaration of Interest</bold></p><p id="P40">A.S. is currently an employee of Altos Labs. I.B. is currently an employee of Novartis. The remaining authors declare no competing interests.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkaissi</surname><given-names>H</given-names></name><name><surname>Taieb</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>FI</given-names></name><name><surname>Del Rivero</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Clifton-Bligh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Approach to the Patient with Metastatic Pheochromocytoma and Paraganglioma</article-title><source>J Clin Endocrinol Metab</source><year>2025</year><pub-id pub-id-type="pmid">40317194</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hescot</surname><given-names>S</given-names></name><name><surname>Curras-Freixes</surname><given-names>M</given-names></name><name><surname>Deutschbein</surname><given-names>T</given-names></name><name><surname>van Berkel</surname><given-names>A</given-names></name><name><surname>Vezzosi</surname><given-names>D</given-names></name><name><surname>Amar</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study</article-title><source>J Clin Endocrinol Metab</source><year>2019</year><volume>104</volume><issue>6</issue><fpage>2367</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">30715419</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayala-Ramirez</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>MM</given-names></name><name><surname>Ejaz</surname><given-names>S</given-names></name><name><surname>Habra</surname><given-names>MA</given-names></name><name><surname>Rich</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><issue>3</issue><fpage>717</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">21190975</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hescot</surname><given-names>S</given-names></name><name><surname>Leboulleux</surname><given-names>S</given-names></name><name><surname>Amar</surname><given-names>L</given-names></name><name><surname>Vezzosi</surname><given-names>D</given-names></name><name><surname>Borget</surname><given-names>I</given-names></name><name><surname>Bournaud-Salinas</surname><given-names>C</given-names></name><etal/></person-group><article-title>One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>10</issue><fpage>4006</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">23884775</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>NGSiPS</surname><given-names>Group</given-names></name><name><surname>Toledo</surname><given-names>RA</given-names></name><name><surname>Burnichon</surname><given-names>N</given-names></name><name><surname>Cascon</surname><given-names>A</given-names></name><name><surname>Benn</surname><given-names>DE</given-names></name><name><surname>Bayley</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas</article-title><source>Nat Rev Endocrinol</source><year>2017</year><volume>13</volume><issue>4</issue><fpage>233</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">27857127</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favier</surname><given-names>J</given-names></name><name><surname>Amar</surname><given-names>L</given-names></name><name><surname>Gimenez-Roqueplo</surname><given-names>AP</given-names></name></person-group><article-title>Paraganglioma and phaeochromocytoma: from genetics to personalized medicine</article-title><source>Nat Rev Endocrinol</source><year>2015</year><volume>11</volume><issue>2</issue><fpage>101</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">25385035</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taieb</surname><given-names>D</given-names></name><name><surname>Nolting</surname><given-names>S</given-names></name><name><surname>Perrier</surname><given-names>ND</given-names></name><name><surname>Fassnacht</surname><given-names>M</given-names></name><name><surname>Carrasquillo</surname><given-names>JA</given-names></name><name><surname>Grossman</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement</article-title><source>Nat Rev Endocrinol</source><year>2024</year><volume>20</volume><issue>3</issue><fpage>168</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">38097671</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lussey-Lepoutre</surname><given-names>C</given-names></name><name><surname>Pacak</surname><given-names>K</given-names></name><name><surname>Grossman</surname><given-names>A</given-names></name><name><surname>Taieb</surname><given-names>D</given-names></name><name><surname>Amar</surname><given-names>L</given-names></name></person-group><article-title>Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2025</year><volume>39</volume><issue>1</issue><elocation-id>101938</elocation-id><pub-id pub-id-type="pmid">39271377</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkova</surname><given-names>H</given-names></name><name><surname>Prodanov</surname><given-names>T</given-names></name><name><surname>Maly</surname><given-names>M</given-names></name><name><surname>Martucci</surname><given-names>V</given-names></name><name><surname>Adams</surname><given-names>K</given-names></name><name><surname>Widimsky</surname><given-names>J</given-names></name><etal/></person-group><article-title>Characteristics and Outcomes of Metastatic Sdhb and Sporadic Pheochromocytoma/Paraganglioma: An National Institutes of Health Study</article-title><source>Endocr Pract</source><year>2016</year><volume>22</volume><issue>3</issue><fpage>302</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.4158/EP15725.OR</pub-id><pub-id pub-id-type="pmcid">PMC7473461</pub-id><pub-id pub-id-type="pmid">26523625</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>A</given-names></name><name><surname>Pattison</surname><given-names>AD</given-names></name><name><surname>Balachander</surname><given-names>S</given-names></name><name><surname>Boehm</surname><given-names>E</given-names></name><name><surname>Bowen</surname><given-names>B</given-names></name><name><surname>Dwight</surname><given-names>T</given-names></name><etal/></person-group><article-title>Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles</article-title><source>Res Sq</source><year>2024</year><pub-id pub-id-type="doi">10.1038/s41467-025-57595-y</pub-id><pub-id pub-id-type="pmcid">PMC11914184</pub-id><pub-id pub-id-type="pmid">40097403</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolting</surname><given-names>S</given-names></name><name><surname>Bechmann</surname><given-names>N</given-names></name><name><surname>Taieb</surname><given-names>D</given-names></name><name><surname>Beuschlein</surname><given-names>F</given-names></name><name><surname>Fassnacht</surname><given-names>M</given-names></name><name><surname>Kroiss</surname><given-names>M</given-names></name><etal/></person-group><article-title>Personalized Management of Pheochromocytoma and Paraganglioma</article-title><source>Endocr Rev</source><year>2022</year><volume>43</volume><issue>2</issue><fpage>199</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1210/endrev/bnab019</pub-id><pub-id pub-id-type="pmcid">PMC8905338</pub-id><pub-id pub-id-type="pmid">34147030</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scriba</surname><given-names>LD</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Santambrogio</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>G</given-names></name><name><surname>Huebner</surname><given-names>A</given-names></name><name><surname>Hauer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cancer Stem Cells in Pheochromocytoma and Paraganglioma</article-title><source>Front Endocrinol (Lausanne)</source><year>2020</year><volume>11</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.3389/fendo.2020.00079</pub-id><pub-id pub-id-type="pmcid">PMC7051940</pub-id><pub-id pub-id-type="pmid">32158431</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudijk</surname><given-names>L</given-names></name><name><surname>Neuhofer</surname><given-names>CM</given-names></name><name><surname>Lichtenauer</surname><given-names>UD</given-names></name><name><surname>Papathomas</surname><given-names>TG</given-names></name><name><surname>Korpershoek</surname><given-names>E</given-names></name><name><surname>Stoop</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations</article-title><source>Eur J Endocrinol</source><year>2015</year><volume>173</volume><issue>1</issue><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">25916394</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santambrogio</surname><given-names>A</given-names></name><name><surname>Kemkem</surname><given-names>Y</given-names></name><name><surname>Willis</surname><given-names>TL</given-names></name><name><surname>Berger</surname><given-names>I</given-names></name><name><surname>Kastriti</surname><given-names>ME</given-names></name><name><surname>Faure</surname><given-names>L</given-names></name><etal/></person-group><article-title>SOX2(+) sustentacular cells are stem cells of the postnatal adrenal medulla</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><issue>1</issue><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-55289-5</pub-id><pub-id pub-id-type="pmcid">PMC11696870</pub-id><pub-id pub-id-type="pmid">39747853</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zethoven</surname><given-names>M</given-names></name><name><surname>Martelotto</surname><given-names>L</given-names></name><name><surname>Pattison</surname><given-names>A</given-names></name><name><surname>Bowen</surname><given-names>B</given-names></name><name><surname>Balachander</surname><given-names>S</given-names></name><name><surname>Flynn</surname><given-names>A</given-names></name><etal/></person-group><article-title>Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><elocation-id>6262</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-34011-3</pub-id><pub-id pub-id-type="pmcid">PMC9587261</pub-id><pub-id pub-id-type="pmid">36271074</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Gomez-Salazar</surname><given-names>M</given-names></name><name><surname>Tower</surname><given-names>RJ</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Morris</surname><given-names>CD</given-names></name><name><surname>McCarthy</surname><given-names>EF</given-names></name><etal/></person-group><article-title>NELL1 Regulates the Matrisome to Promote Osteosarcoma Progression</article-title><source>Cancer Res</source><year>2022</year><volume>82</volume><issue>15</issue><fpage>2734</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-22-0732</pub-id><pub-id pub-id-type="pmcid">PMC9357190</pub-id><pub-id pub-id-type="pmid">35700263</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>R</given-names></name><name><surname>Boguszewski</surname><given-names>CL</given-names></name><name><surname>Kopchick</surname><given-names>JJ</given-names></name></person-group><article-title>Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies</article-title><source>Endocr Rev</source><year>2025</year><volume>46</volume><issue>2</issue><fpage>224</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">39657053</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arumugam</surname><given-names>A</given-names></name><name><surname>Subramani</surname><given-names>R</given-names></name><name><surname>Nandy</surname><given-names>SB</given-names></name><name><surname>Terreros</surname><given-names>D</given-names></name><name><surname>Dwivedi</surname><given-names>AK</given-names></name><name><surname>Saltzstein</surname><given-names>E</given-names></name><etal/></person-group><article-title>Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2</article-title><source>Exp Mol Med</source><year>2019</year><volume>51</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s12276-018-0197-8</pub-id><pub-id pub-id-type="pmcid">PMC6323053</pub-id><pub-id pub-id-type="pmid">30617282</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Zhen</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Ke</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma</article-title><source>Aging (Albany NY)</source><year>2022</year><volume>14</volume><issue>18</issue><fpage>7416</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.18632/aging.204280</pub-id><pub-id pub-id-type="pmcid">PMC9550261</pub-id><pub-id pub-id-type="pmid">36098680</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6/E2F1 positive feedback loop in lung adenocarcinoma</article-title><source>Cancer Commun (Lond)</source><year>2021</year><volume>41</volume><issue>6</issue><fpage>492</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1002/cac2.12155</pub-id><pub-id pub-id-type="pmcid">PMC8211349</pub-id><pub-id pub-id-type="pmid">33734616</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Genetic network and gene set enrichment analyses identify MND1 as potential diagnostic and therapeutic target gene for lung adenocarcinoma</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><elocation-id>9430</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-88948-4</pub-id><pub-id pub-id-type="pmcid">PMC8093199</pub-id><pub-id pub-id-type="pmid">33941804</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><etal/></person-group><article-title>CREB5 promotes invasiveness and metastasis in colorectal cancer by directly activating MET</article-title><source>J Exp Clin Cancer Res</source><year>2020</year><volume>39</volume><issue>1</issue><fpage>168</fpage><pub-id pub-id-type="doi">10.1186/s13046-020-01673-0</pub-id><pub-id pub-id-type="pmcid">PMC7446182</pub-id><pub-id pub-id-type="pmid">32843066</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of CREB5 as a prognostic and immunotherapeutic biomarker in glioma through multi-omics pan-cancer analysis</article-title><source>Comput Biol Med</source><year>2024</year><volume>173</volume><elocation-id>108307</elocation-id><pub-id pub-id-type="pmid">38547657</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>P</given-names></name><name><surname>Shankar</surname><given-names>E</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name></person-group><article-title>EZH2-mediated development of therapeutic resistance in cancer</article-title><source>Cancer Lett</source><year>2024</year><volume>586</volume><elocation-id>216706</elocation-id><pub-id pub-id-type="pmid">38331087</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Roberts</surname><given-names>CW</given-names></name></person-group><article-title>Targeting EZH2 in cancer</article-title><source>Nat Med</source><year>2016</year><volume>22</volume><issue>2</issue><fpage>128</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/nm.4036</pub-id><pub-id pub-id-type="pmcid">PMC4918227</pub-id><pub-id pub-id-type="pmid">26845405</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Lyu</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>PIMREG is a prognostic biomarker involved in immune microenvironment of clear cell renal cell carcinoma and associated with the transition from G1 phase to S phase</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><elocation-id>1035321</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2023.1035321</pub-id><pub-id pub-id-type="pmcid">PMC9909346</pub-id><pub-id pub-id-type="pmid">36776322</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>J</given-names></name></person-group><article-title>Oncogenic role and prognostic significance of PIMREG in melanoma</article-title><source>Transl Cancer Res</source><year>2025</year><volume>14</volume><issue>2</issue><fpage>1070</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.21037/tcr-24-1861</pub-id><pub-id pub-id-type="pmcid">PMC11912051</pub-id><pub-id pub-id-type="pmid">40104736</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-kappaB signaling</article-title><source>EBioMedicine</source><year>2019</year><volume>43</volume><fpage>188</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.04.001</pub-id><pub-id pub-id-type="pmcid">PMC6557765</pub-id><pub-id pub-id-type="pmid">30979686</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>JV</given-names></name><name><surname>Nicolau-Neto</surname><given-names>P</given-names></name><name><surname>de Almeida</surname><given-names>JN</given-names></name><name><surname>Lisboa</surname><given-names>LB</given-names></name><name><surname>de Souza-Santos</surname><given-names>PT</given-names></name><name><surname>Ribeiro-Pinto</surname><given-names>LF</given-names></name><etal/></person-group><article-title>HOXA7 Expression Is an Independent Prognostic Biomarker in Esophageal Squamous Cell Carcinoma</article-title><source>Genes (Basel)</source><year>2024</year><volume>15</volume><issue>11</issue><pub-id pub-id-type="doi">10.3390/genes15111430</pub-id><pub-id pub-id-type="pmcid">PMC11593377</pub-id><pub-id pub-id-type="pmid">39596630</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells</article-title><source>Cancer Cell Int</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/s12935-022-02519-9</pub-id><pub-id pub-id-type="pmcid">PMC8858502</pub-id><pub-id pub-id-type="pmid">35183163</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name></person-group><article-title>miR-17-5p/HOXA7 Is a Potential Driver for Brain Metastasis of Lung Adenocarcinoma Related to Ferroptosis Revealed by Bioinformatic Analysis</article-title><source>Front Neurol</source><year>2022</year><volume>13</volume><elocation-id>878947</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2022.878947</pub-id><pub-id pub-id-type="pmcid">PMC9174431</pub-id><pub-id pub-id-type="pmid">35693013</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouge</surname><given-names>J</given-names></name><name><surname>Satia</surname><given-names>K</given-names></name><name><surname>Guthertz</surname><given-names>N</given-names></name><name><surname>Widya</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Cousin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Redox Signaling by the RNA Polymerase III TFIIB-Related Factor Brf2</article-title><source>Cell</source><year>2015</year><volume>163</volume><issue>6</issue><fpage>1375</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.005</pub-id><pub-id pub-id-type="pmcid">PMC4671959</pub-id><pub-id pub-id-type="pmid">26638071</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashidieh</surname><given-names>B</given-names></name><name><surname>Molakarimi</surname><given-names>M</given-names></name><name><surname>Mohseni</surname><given-names>A</given-names></name><name><surname>Tria</surname><given-names>SM</given-names></name><name><surname>Truong</surname><given-names>H</given-names></name><name><surname>Srihari</surname><given-names>S</given-names></name><etal/></person-group><article-title>Targeting BRF2 in Cancer Using Repurposed Drugs</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><issue>15</issue><pub-id pub-id-type="doi">10.3390/cancers13153778</pub-id><pub-id pub-id-type="pmcid">PMC8345145</pub-id><pub-id pub-id-type="pmid">34359683</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capone</surname><given-names>E</given-names></name><name><surname>Iacobelli</surname><given-names>S</given-names></name><name><surname>Sala</surname><given-names>G</given-names></name></person-group><article-title>Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target</article-title><source>J Transl Med</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>405</fpage><pub-id pub-id-type="doi">10.1186/s12967-021-03085-w</pub-id><pub-id pub-id-type="pmcid">PMC8474792</pub-id><pub-id pub-id-type="pmid">34565385</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Wnt/beta-Catenin Signaling, Disease, and Emerging Therapeutic Modalities</article-title><source>Cell</source><year>2017</year><volume>169</volume><issue>6</issue><fpage>985</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">28575679</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugter</surname><given-names>JM</given-names></name><name><surname>Fenderico</surname><given-names>N</given-names></name><name><surname>Maurice</surname><given-names>MM</given-names></name></person-group><article-title>Mutations and mechanisms of WNT pathway tumour suppressors in cancer</article-title><source>Nat Rev Cancer</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>5</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">33097916</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>T</given-names></name><name><surname>Rindtorff</surname><given-names>N</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name></person-group><article-title>Wnt signaling in cancer</article-title><source>Oncogene</source><year>2017</year><volume>36</volume><issue>11</issue><fpage>1461</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.304</pub-id><pub-id pub-id-type="pmcid">PMC5357762</pub-id><pub-id pub-id-type="pmid">27617575</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitrov</surname><given-names>D</given-names></name><name><surname>Schafer</surname><given-names>PSL</given-names></name><name><surname>Farr</surname><given-names>E</given-names></name><name><surname>Rodriguez-Mier</surname><given-names>P</given-names></name><name><surname>Lobentanzer</surname><given-names>S</given-names></name><name><surname>Badia</surname><given-names>IMP</given-names></name><etal/></person-group><article-title>LIANA+ provides an all-in-one framework for cell-cell communication inference</article-title><source>Nat Cell Biol</source><year>2024</year><volume>26</volume><issue>9</issue><fpage>1613</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/s41556-024-01469-w</pub-id><pub-id pub-id-type="pmcid">PMC11392821</pub-id><pub-id pub-id-type="pmid">39223377</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>K</given-names></name><name><surname>Yatsyna</surname><given-names>A</given-names></name><name><surname>Charbonneau</surname><given-names>M</given-names></name><name><surname>Brochu-Gaudreau</surname><given-names>K</given-names></name><name><surname>Perreault</surname><given-names>A</given-names></name><name><surname>Jeldres</surname><given-names>C</given-names></name><etal/></person-group><article-title>The Chicken Chorioallantoic Membrane Tumor Assay as a Relevant In Vivo Model to Study the Impact of Hypoxia on Tumor Progression and Metastasis</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><issue>5</issue><pub-id pub-id-type="doi">10.3390/cancers13051093</pub-id><pub-id pub-id-type="pmcid">PMC7961795</pub-id><pub-id pub-id-type="pmid">33806378</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribatti</surname><given-names>D</given-names></name></person-group><article-title>The chick embryo chorioallantoic membrane (CAM). A multifaceted experimental model</article-title><source>Mech Dev</source><year>2016</year><volume>141</volume><fpage>70</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">27178379</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busch</surname><given-names>C</given-names></name><name><surname>Krochmann</surname><given-names>J</given-names></name><name><surname>Drews</surname><given-names>U</given-names></name></person-group><article-title>The chick embryo as an experimental system for melanoma cell invasion</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>1</issue><elocation-id>e53970</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0053970</pub-id><pub-id pub-id-type="pmcid">PMC3544663</pub-id><pub-id pub-id-type="pmid">23342051</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunzi-Rapp</surname><given-names>K</given-names></name><name><surname>Genze</surname><given-names>F</given-names></name><name><surname>Kufer</surname><given-names>R</given-names></name><name><surname>Reich</surname><given-names>E</given-names></name><name><surname>Hautmann</surname><given-names>RE</given-names></name><name><surname>Gschwend</surname><given-names>JE</given-names></name></person-group><article-title>Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model</article-title><source>J Urol</source><year>2001</year><volume>166</volume><issue>4</issue><fpage>1502</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11547121</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Scanlon</surname><given-names>CS</given-names></name><name><surname>Banerjee</surname><given-names>R</given-names></name><name><surname>Russo</surname><given-names>N</given-names></name><name><surname>Inglehart</surname><given-names>RC</given-names></name><name><surname>Willis</surname><given-names>AL</given-names></name><etal/></person-group><article-title>The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma</article-title><source>Transl Oncol</source><year>2013</year><volume>6</volume><issue>3</issue><fpage>273</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1593/tlo.13175</pub-id><pub-id pub-id-type="pmcid">PMC3660795</pub-id><pub-id pub-id-type="pmid">23730406</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lokman</surname><given-names>NA</given-names></name><name><surname>Elder</surname><given-names>ASF</given-names></name><name><surname>Ricciardelli</surname><given-names>C</given-names></name><name><surname>Oehler</surname><given-names>MK</given-names></name></person-group><article-title>Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis</article-title><source>Int J Mol Sci</source><year>2012</year><volume>13</volume><issue>8</issue><fpage>9959</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.3390/ijms13089959</pub-id><pub-id pub-id-type="pmcid">PMC3431839</pub-id><pub-id pub-id-type="pmid">22949841</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visvader</surname><given-names>JE</given-names></name><name><surname>Lindeman</surname><given-names>GJ</given-names></name></person-group><article-title>Cancer stem cells: current status and evolving complexities</article-title><source>Cell Stem Cell</source><year>2012</year><volume>10</volume><issue>6</issue><fpage>717</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">22704512</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>JJ</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name></person-group><article-title>Hallmarks of cancer stemness</article-title><source>Cell Stem Cell</source><year>2024</year><volume>31</volume><issue>5</issue><fpage>617</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">38701757</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Hawkins</surname><given-names>C</given-names></name><name><surname>Clarke</surname><given-names>ID</given-names></name><name><surname>Squire</surname><given-names>JA</given-names></name><name><surname>Bayani</surname><given-names>J</given-names></name><name><surname>Hide</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of human brain tumour initiating cells</article-title><source>Nature</source><year>2004</year><volume>432</volume><issue>7015</issue><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">15549107</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suetsugu</surname><given-names>A</given-names></name><name><surname>Nagaki</surname><given-names>M</given-names></name><name><surname>Aoki</surname><given-names>H</given-names></name><name><surname>Motohashi</surname><given-names>T</given-names></name><name><surname>Kunisada</surname><given-names>T</given-names></name><name><surname>Moriwaki</surname><given-names>H</given-names></name></person-group><article-title>Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>351</volume><issue>4</issue><fpage>820</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">17097610</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreso</surname><given-names>A</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name></person-group><article-title>Evolution of the cancer stem cell model</article-title><source>Cell Stem Cell</source><year>2014</year><volume>14</volume><issue>3</issue><fpage>275</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">24607403</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Hajj</surname><given-names>M</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><name><surname>Benito-Hernandez</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name></person-group><article-title>Prospective identification of tumorigenic breast cancer cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><issue>7</issue><fpage>3983</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1073/pnas.0530291100</pub-id><pub-id pub-id-type="pmcid">PMC153034</pub-id><pub-id pub-id-type="pmid">12629218</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>C</given-names></name><name><surname>Xi</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A unified model of the hierarchical and stochastic theories of gastric cancer</article-title><source>Br J Cancer</source><year>2017</year><volume>116</volume><issue>8</issue><fpage>973</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.54</pub-id><pub-id pub-id-type="pmcid">PMC5396111</pub-id><pub-id pub-id-type="pmid">28301871</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesh</surname><given-names>K</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>Targeting metastatic cancer</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><issue>1</issue><fpage>34</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01195-4</pub-id><pub-id pub-id-type="pmcid">PMC7895475</pub-id><pub-id pub-id-type="pmid">33442008</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peitzsch</surname><given-names>C</given-names></name><name><surname>Tyutyunnykova</surname><given-names>A</given-names></name><name><surname>Pantel</surname><given-names>K</given-names></name><name><surname>Dubrovska</surname><given-names>A</given-names></name></person-group><article-title>Cancer stem cells: The root of tumor recurrence and metastases</article-title><source>Semin Cancer Biol</source><year>2017</year><volume>44</volume><fpage>10</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">28257956</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>JM</given-names></name><name><surname>Jordan</surname><given-names>CT</given-names></name></person-group><article-title>The increasing complexity of the cancer stem cell paradigm</article-title><source>Science</source><year>2009</year><volume>324</volume><issue>5935</issue><fpage>1670</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1126/science.1171837</pub-id><pub-id pub-id-type="pmcid">PMC2873047</pub-id><pub-id pub-id-type="pmid">19556499</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haston</surname><given-names>S</given-names></name><name><surname>Gonzalez-Gualda</surname><given-names>E</given-names></name><name><surname>Morsli</surname><given-names>S</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Reen</surname><given-names>V</given-names></name><name><surname>Calderwood</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><issue>7</issue><fpage>1242</fpage><lpage>60</lpage><elocation-id>e6</elocation-id><pub-id pub-id-type="pmid">37267953</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andoniadou</surname><given-names>CL</given-names></name><name><surname>Matsushima</surname><given-names>D</given-names></name><name><surname>Mousavy Gharavy</surname><given-names>SN</given-names></name><name><surname>Signore</surname><given-names>M</given-names></name><name><surname>Mackintosh</surname><given-names>AI</given-names></name><name><surname>Schaeffer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential</article-title><source>Cell Stem Cell</source><year>2013</year><volume>13</volume><issue>4</issue><fpage>433</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">24094324</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Pineda</surname><given-names>CM</given-names></name><name><surname>Xin</surname><given-names>T</given-names></name><name><surname>Boucher</surname><given-names>J</given-names></name><name><surname>Suozzi</surname><given-names>KC</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><etal/></person-group><article-title>Correction of aberrant growth preserves tissue homeostasis</article-title><source>Nature</source><year>2017</year><volume>548</volume><issue>7667</issue><fpage>334</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature23304</pub-id><pub-id pub-id-type="pmcid">PMC5675114</pub-id><pub-id pub-id-type="pmid">28783732</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deschene</surname><given-names>ER</given-names></name><name><surname>Myung</surname><given-names>P</given-names></name><name><surname>Rompolas</surname><given-names>P</given-names></name><name><surname>Zito</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>TY</given-names></name><name><surname>Taketo</surname><given-names>MM</given-names></name><etal/></person-group><article-title>beta-Catenin activation regulates tissue growth non-cell autonomously in the hair stem cell niche</article-title><source>Science</source><year>2014</year><volume>343</volume><issue>6177</issue><fpage>1353</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.1248373</pub-id><pub-id pub-id-type="pmcid">PMC4096864</pub-id><pub-id pub-id-type="pmid">24653033</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Fei</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Glioma initiating cells contribute to malignant transformation of host glial cells during tumor tissue remodeling via PDGF signaling</article-title><source>Cancer Lett</source><year>2015</year><volume>365</volume><issue>2</issue><fpage>174</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26049020</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Sheng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Downregulation of miRNA-146a-5p promotes malignant transformation of mesenchymal stromal/stem cells by glioma stem-like cells</article-title><source>Aging (Albany NY)</source><year>2020</year><volume>12</volume><issue>10</issue><fpage>9151</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.18632/aging.103185</pub-id><pub-id pub-id-type="pmcid">PMC7288935</pub-id><pub-id pub-id-type="pmid">32452829</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thliveris</surname><given-names>AT</given-names></name><name><surname>Schwefel</surname><given-names>B</given-names></name><name><surname>Clipson</surname><given-names>L</given-names></name><name><surname>Plesh</surname><given-names>L</given-names></name><name><surname>Zahm</surname><given-names>CD</given-names></name><name><surname>Leystra</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Transformation of epithelial cells through recruitment leads to polyclonal intestinal tumors</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><issue>28</issue><fpage>11523</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303064110</pub-id><pub-id pub-id-type="pmcid">PMC3710880</pub-id><pub-id pub-id-type="pmid">23798428</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Immunohistochemistry using antibodies against SOX2 on FFPE sections of phaeochromocytomas and paragangliomas (PPGLs).</title><p>In all panels, cells immunopositive for SOX2 are in brown, cells counterstained with haematoxylin. (A) Non-metastatic phaeochromocytomas PCC1 to PCC3 with mutations in NF1. (B) Non-metastatic phaeochromocytoma PCC4 with mutation in <italic>SDHC</italic>; (C) Non-metastatic phaeochromocytomas PCC5 to PCC7 with mutations in <italic>RET</italic> (D) Malignant phaeochromocytoma PCC8 and non-malignant paraganglioma PGL9 with mutations in <italic>VHL</italic> (E) Non-malignant paragangliomas PGL12 to PGL14 and malignant paragangliomas PGL15 to PGL17 with mutations in <italic>SDHB</italic> (F) Non-malignant phaeochromocytomas PCC10 and PCC11 with no known mutations. (G) Malignant phaeochromocytomas PCC12 and PCC13 with no known mutations. Scale bars 50μm.</p></caption><graphic xlink:href="EMS207185-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Single-cell analysis of PPGLs identifies expression of SOX2 in tumour chromaffin cells.</title><p>(A) UMAP plot of the integrated dataset with each cell type (left) and patient group (right - healthy vs tumour) coloured separately. (B) Dotplot of key markers associated with the identified cell populations. (C) Heatmap of the top marker genes in sustentacular cells ordered by statistical significance from top to bottom. Colours correspond to gene-wise min-max normalised values. (D) Stacked barplot of cell type proportions in each sequenced sample; (E) Heatmap of top marker genes in chromaffin tumour cells comparing metastatic (left) to non-metastatic (right) samples. Genes were ranked by statistical significance from top to bottom for upregulated genes (for metastatic) and bottom to top for downregulated genes. Colours correspond to gene-wise min-max normalised values. (F) UMAP plot of normalised <italic>SOX2</italic> expression across all tumour cells, with the dots ordered by their expression values. (G) UMAP showing <italic>SOX2</italic> (blue), <italic>MKI67</italic> (cycling cells, yellow) and double-positive cells (red). Cells were classified as positive if they had at least a single transcript. (H) Strip plot of the proportion of <italic>SOX2</italic>+ cells in each sample. Distances on the Y-axis are on a log10 scale, and for visualisation purposes, datasets with 0% SOX2+ were plotted at Y=0.0001. Jitter has been added to the X-axis to reduce overlapping observations. (I) Heatmap of top transcription factor-encoding genes distinguishing chromaffin tumour cells in tumours with high SOX2+ cell proportion, from chromaffin tumour cells in tumours with low SOX2+ cell proportion, as determined with a 1% cut-off (see H). Genes are ordered by statistical significance from top to bottom. Colours correspond to gene-wise min-max normalised values. (J) Heatmap of genes associated with signalling, distinguishing chromaffin tumour cells in tumours with high SOX2+ cell proportion, from chromaffin tumour cells in tumours with low SOX2+ cell proportion, as determined with a 1% cut-off (see H). Genes are ordered by statistical significance from top to bottom. Colours correspond to gene-wise min-max normalised values. (K) LIANA+ dotplot with of the top 20 interactions where chromaffin cells are the source and ordered by specificity rank. Colours correspond to magnitude while dot size increases with specificity rank, as calculated by LIANA+.</p></caption><graphic xlink:href="EMS207185-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>In vitro isolation and characterisation of PPGL-derived stem cells.</title><p>(A) Immunohistochemistry confirming the presence of SOX2+ cells in foetal adrenal medullae at 12 post-conception weeks (PCW), 17PCW and 19PCW. SOX2 positive cells in brown, tissues counterstained with haematoxylin. Scale bars 100μm. (B) <italic>In vitro</italic> isolation of foetal adrenomedullary cells at 19PCW leads to the generation of adherent colonies from 3 days under defined stem cell-promoting media. Scale bars 50μm. <italic>In vitro</italic> isolation of adult adrenomedullary cells from PCC30 benign phaeochromocytoma with no known mutations and PGL33, malignant paraganglioma with a germline mutation in <italic>SDHD</italic>, under defined stem cell-promoting media. Adherent cells and colonies seen at 24 and 96 hours. Scale bars 50μm. (C) Immunofluorescence using antibodies against SOX2 and TH confirms protein expression in PCC30 adherent colonies after two weeks in culture. Scale bars 50μm.</p></caption><graphic xlink:href="EMS207185-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>SOX2+ PPGL stem cells have tumour-inducing and metastatic capacity in ovo.</title><p>(A) Single-cell suspension and labelling of foetal 19PCW cells with CellTracker green CMFDA label. Scale bars 500μm. (B) Pipeline for the <italic>in vitro</italic> isolation and <italic>in ovo</italic> transplantation of human SOX2+ cells (schematic created in <ext-link ext-link-type="uri" xlink:href="https://BioRender.com">BioRender.com</ext-link>). (C) Chick chorioallantoic membrane (CAM) xenograft of PGL33 after 4 days of incubation. Brightfield and UV fluorescence images of the dissected CAM, with a visible cell mass established on the vascularised CAM. The silicon O-ring is visible. Red and yellow boxes indicate the magnified regions shown below, depicting the mass. (D) Immunostaining on formalin-fixed, paraffin sections of the xenograft in C. Immunofluorescence using antibodies against human nuclear antigen (HNA, red)) confirming the presence of human cells in the mass. Nuclei counterstained with DAPI. Immunohistochemistry with antibodies against SOX2 (brown), confirming the presence of SOX2-expressing cells. Nuclei counterstained with haematoxylin. Scale bars 100μm. (E) Cryosections through the lungs of chicks where CAMs were successfully grafted with either foetal adrenal stem cell cultures, isolated stem cell cultures from PCC30 or isolated stem cell cultures from PGL33. Green fluorescent cells are detected in PGL33 cultures confirming metastasis. Nuclei counterstained with DAPI. Scale bars 100μm, except on right-hand panels where scale bars are 20μm. (F) Immunofluorescence staining on cryosections through chick lungs of a PGL33 xenograft with metastasis, using antibodies against SOX2 (magenta) and TH (green). Nuclei counterstained with DAPI (blue). The greyscale images of single channels are shown for signal clarity. Yellow arrows indicate SOX2 positive cells, green arrows indicate TH positive cells and white arrows indicate SOX2;TH double-positive cells. Nuclei counterstained with DAPI. Scale bars 50μm. XenoT = xenotransplanted.</p></caption><graphic xlink:href="EMS207185-f004"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Details of tumour samples analysed by immunohistochemistry in <xref ref-type="fig" rid="F1">Figure 1</xref>.</title></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left">Tumour ID</th><th valign="top" align="left">Tumour type</th><th valign="top" align="left">Tumour status</th><th valign="top" align="left">Metastasis</th><th valign="top" align="center" colspan="2">Variant identified</th></tr><tr><th valign="top" align="left"/><th valign="top" align="left"/><th valign="top" align="left"/><th valign="top" align="left"/><th valign="top" align="left">Confirmed germline mutation</th><th valign="top" align="left">Confirmed somatic mutation</th></tr></thead><tbody><tr><td valign="top" align="left">PCC1</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left"><italic>NF1</italic> - no variant stated</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PCC2</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left"><italic>NF1</italic> - no variant stated</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PCC3</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left"><italic>NF1</italic> - no variant stated</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PCC4</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left"><italic>SDHC</italic> - no variant stated</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PCC5</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">None</td><td valign="top" align="left"><italic>RET</italic> - no variant stated</td></tr><tr><td valign="top" align="left">PCC6</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left"><italic>RET</italic>- no variant stated</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PCC7</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Unknown</td><td valign="top" align="left"><italic>RET</italic> - no variant stated</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PGL8</td><td valign="top" align="left">Carotid body Paraganglioma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">None</td><td valign="top" align="left"><italic>VHL</italic> - no variant stated</td></tr><tr><td valign="top" align="left">PCC9</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">None</td><td valign="top" align="left"><italic>VHL</italic> - no variant stated</td></tr><tr><td valign="top" align="left">PCC10</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Unknown</td><td valign="top" align="left">None</td><td valign="top" align="left">None</td></tr><tr><td valign="top" align="left">PCC11</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Unknown</td><td valign="top" align="left">None</td><td valign="top" align="left">None</td></tr><tr><td valign="top" align="left">PGL12</td><td valign="top" align="left">Mediastinal Paraganglioma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left"><italic>SDHB</italic> - C.136C&gt;T</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PGL13</td><td valign="top" align="left">Retroperitoneal Paraganglioma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Unknown</td><td valign="top" align="left"><italic>SDHB</italic> - deletion exon 1</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PGL14</td><td valign="top" align="left">Carotid body Paraganglioma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Yes</td><td valign="top" align="left"><italic>SDHB</italic> - no variant stated</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PGL15</td><td valign="top" align="left">Abdominal para-aortic Paraganglioma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Yes</td><td valign="top" align="left"><italic>SDHB - C.268</italic>C&gt;<italic>T, pArg90*</italic></td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PGL16</td><td valign="top" align="left">Abdominal para-aortic Paraganglioma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Yes</td><td valign="top" align="left"><italic>SDHB</italic> - c.338G&gt;A, p.Cys113Tyr</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PGL17</td><td valign="top" align="left">Mediastinal Paraganglioma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left"><italic>SDHB</italic> - C.79C&gt;T, pArg27*</td><td valign="top" align="left"/></tr><tr><td valign="top" align="left">PCC18</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Yes</td><td valign="top" align="left">None</td><td valign="top" align="left">None</td></tr><tr><td valign="top" align="left">PCC19</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Yes</td><td valign="top" align="left">None</td><td valign="top" align="left">None</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Details of tumour samples used for transcriptomic analyses.</title></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left">Source</th><th valign="top" align="left">Tumour ID in original<break/>publication</th><th valign="top" align="left">Tumour ID in this<break/>publication</th><th valign="top" align="left">Tumour Type</th><th valign="top" align="left">Single Cell or<break/>Single</th><th valign="top" align="left">Tumour status</th><th valign="top" align="left">Metastasis</th><th valign="top" align="left">Metastasis site</th><th valign="top" align="left">Variant identified</th><th valign="top" align="left"><italic>SOX2+</italic> cells</th></tr></thead><tbody><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E019-P1</td><td valign="top" align="left">PGL20</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHB</italic> c.418G&gt;T</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E123-M1</td><td valign="top" align="left">PGL21</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Metastasis</td><td valign="top" align="left">Yes</td><td valign="top" align="left">Bone</td><td valign="top" align="left"><italic>SDHB</italic> C.380T&gt;G</td><td valign="top" align="left">No</td></tr><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E140-P1</td><td valign="top" align="left">PCC22</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHB</italic> C.380T&gt;G</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E143-M1</td><td valign="top" align="left">PGL23</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Metastasis</td><td valign="top" align="left">Yes</td><td valign="top" align="left">Abdominal</td><td valign="top" align="left"><italic>SDHB</italic> C.268C&gt;T</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E146-P1</td><td valign="top" align="left">PGL24</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHB</italic> C.136C&gt;T</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E156-P1</td><td valign="top" align="left">PGL25</td><td valign="top" align="left">Bladder Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHB</italic> C.526G&gt;T</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E166-M1</td><td valign="top" align="left">PGL26</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Metastasis</td><td valign="top" align="left">Yes</td><td valign="top" align="left">Abdominal</td><td valign="top" align="left"><italic>SDHB</italic> C.72+1G&gt;T</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E171-M1</td><td valign="top" align="left">PGL27</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Metastasis</td><td valign="top" align="left">Yes</td><td valign="top" align="left">Chest wall - left rib 5-9</td><td valign="top" align="left"><italic>SDHB</italic> c.736A&gt;T</td><td valign="top" align="left">No</td></tr><tr><td valign="top" align="left">Flynn etal. 2025</td><td valign="top" align="left">E197-M1</td><td valign="top" align="left">PGL28</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Metastasis</td><td valign="top" align="left">Yes</td><td valign="top" align="left">Thoracic mediastinum lymph node</td><td valign="top" align="left"><italic>SDHB</italic> c.1_72del</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Flynn et al. 2025</td><td valign="top" align="left">E225-P1</td><td valign="top" align="left">PGL29</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHB</italic> C.190delG</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">This publication</td><td valign="top" align="left">NA</td><td valign="top" align="left">PCC30</td><td valign="top" align="left">Phaeochromocytoma</td><td valign="top" align="left">SC</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left">None</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">This publication</td><td valign="top" align="left">NA</td><td valign="top" align="left">PGL31</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">sc</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHB</italic> C.268C&gt;T p(Arg90Ter)</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">This publication</td><td valign="top" align="left">NA</td><td valign="top" align="left">PGL32</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">sc</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Yes</td><td valign="top" align="left">Skeletal</td><td valign="top" align="left">None</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">This publication</td><td valign="top" align="left">NA</td><td valign="top" align="left">PGL33</td><td valign="top" align="left">Carotid body Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">Yes</td><td valign="top" align="left">Pulmonary</td><td valign="top" align="left"><italic>SDHD</italic> C.337_340del p.(Asp113fs)</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">This publication</td><td valign="top" align="left">NA</td><td valign="top" align="left">PGL34</td><td valign="top" align="left">Abdominal Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHB</italic> C.268C&gt;T p.(Arg90*)</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">This publication</td><td valign="top" align="left">NA</td><td valign="top" align="left">PGL35</td><td valign="top" align="left">Pelvic Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHB</italic> Exon 1 Deletion</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">This publication</td><td valign="top" align="left">NA</td><td valign="top" align="left">PGL36</td><td valign="top" align="left">Carotid Body Paraganglioma</td><td valign="top" align="left">SN</td><td valign="top" align="left">Primary</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left"><italic>SDHD</italic> C.242C&gt;T, p.(P81L)</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Zethoven et al. 2022</td><td valign="top" align="left">E240</td><td valign="top" align="left">Healthy 1</td><td valign="top" align="left">NA</td><td valign="top" align="left">SN</td><td valign="top" align="left">NA</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td><td valign="top" align="left">Yes</td></tr><tr><td valign="top" align="left">Zethoven et al. 2022</td><td valign="top" align="left">E243</td><td valign="top" align="left">Healthy 2</td><td valign="top" align="left">NA</td><td valign="top" align="left">SN</td><td valign="top" align="left">NA</td><td valign="top" align="left">No</td><td valign="top" align="left">NA</td><td valign="top" align="left">NA</td><td valign="top" align="left">Yes</td></tr></tbody></table></table-wrap></floats-group></article>